Clinical Trials

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT07402473 2026-02-11

EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer

50 enrolled

Phase 2/3 Not yet recruiting

HER2-positive Early-stage Breast Cancer

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

HER2-positive Gastric Cancer

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07136428 2025-12-19

ASCENdANT

42 enrolled

HER2+ Metastatic Breast Cancer

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

188 enrolled

Breast Neoplasms

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

164 enrolled

Breast Neoplasms

NCT07220135 2025-10-23

NeoTHERa

100 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06027983 2025-09-23

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

36 enrolled

BreastOther solid neoplasm

HER2+ Advanced Breast Cancer

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

HER2-positive Breast Cancer

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

80 enrolled

Phase 4 Not yet recruiting

HER2-positive Breast Cancer

NCT07093931 2025-07-30

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

468 enrolled

Breast Neoplasms

NCT06589830 2025-05-15

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

80 enrolled

Neoplasms, Colorectal Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

140 enrolled

Stomach Neoplasms

NCT06510465 2024-07-19

NeoURANIA

143 enrolled

Breast Neoplasms

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

42 enrolled

HER2-positive Gastric Cancer

NCT05983094 2023-08-09

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

181 enrolled

Breast Neoplasms

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

420 enrolled

HER2-positive Advanced Breast Cancer

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

876 enrolled

Breast Neoplasms

NCT05388500 2022-05-27

PHARE-C

800 enrolled

HER2-positive Breast Cancer

NCT05131893 2021-11-23

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting

300 enrolled

Breast Neoplasms

NCT04973319 2021-07-22

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

450 enrolled

Breast Neoplasms

NCT04922008 2021-06-10

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

356 enrolled

Breast Neoplasms

NCT04337658 2020-04-08

FAVOR

493 enrolled

Breast Neoplasms

NCT04158856 2019-11-12

SHERO

60 enrolled